Cadence Pharmaceuticals

Cadence Pharmaceuticals is a biopharmaceutical company focused on licensing, developing, and commercializing proprietary products primarily for the hospital setting. The company's lead product: OFIRMEVTM, is the first and only intravenous formulation of acetaminophen for mild to moderate pain. Cadence received FDA approval for Ofirmev in 2011 and launched the drug, offering post-surgical hospital patients a new non-opioid option for pain management.